Alexey S. Moiseev

Alexey S. Moiseev

Auto-generated profile, based on publicly available information

Alexey S. Moiseev

Tareev Clinic of Internal Diseases, I. Sechenov First Moscow State Medical University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2022 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
LALarisa A. Akulkina
Larisa A. Akulkina
ASAnastasia Shchepalina
Anastasia Shchepalina
AKAram A. Kitbalian
Aram A. Kitbalian
PPPavel P. Potapov
Pavel P. Potapov
AMAlexey S. Moiseev
Alexey S. Moiseev
ЩАЩепалина Анастасия Александровна
Щепалина Анастасия Александровна
Treatment of patients with long-term persistent symptoms after COVID-19 is an urgent problem for clinicians around the world. One of the most significant manifestations of post-COVID-19 syndrome is organizing pneumonia that is usually treat with corticosteroids. The paper presents a clinical case of typical course of post-COVID-19 organizing pneumonia in a patient without previous lung disease. Risk factors, diagnostic methods and treatment options in this group of patients are also discuss.

26 April 2023 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
LAL A Akulkina
L A Akulkina
ASAnastasia Shchepalina
Anastasia Shchepalina
AMA S Moiseev
A S Moiseev
MBM Y Brovko
M Y Brovko
VSVictoria Sholomova
Victoria Sholomova
SMSergey V. Moiseev
Sergey V. Moiseev
Aim. To study demographic, clinical, serological and morphological features of interstitial pneumonia with autoimmune features (IPAF), compare survival in IPAF and interstitial lung disease in connective tissue diseases (CTD-ILD), and identify predictors of mortality and transformation to CTD in the IPAF group. Materials and methods. The IPAF group included 48 patients (75.0% women, median age 57.5 years), CTD-ILD 49 patients (79.6% women, median age 60.0 years). The analysis of demographic, clinical, laboratory and instrumental data was performed, as well as comparison of survival with the KaplanMeier method and the log-rank test in the IPAF and CTD-ILD groups. In the IPAF group, predictors of mortality and the development of CTD were studied with multivariate regression analysis. Results. Duration of observation period did not differ significantly in the IPAF and CTD-ILD groups (40.0 and 37.0 months, respectively). Clinical criteria of IPAF were observed in 25 (52.1%) patients, serological in 44 (91.7%), morphological in 44 (91.7%). Mortality in the IPAF group was significantly higher than in the CTD-ILD group (29.2 and 6.1%, respectively; p=0.023). The presence of diabetes mellitus, CT-pattern of usual interstitial pneumonia, and an initial low forced vital capacity value were independent predictors of mortality in the IPAF group. During the observation period, the development of CTD was noted in 4 (8.3%) patients with IPAF. The independent predictor of the CTD development was the increased C-reactive protein level. Conclusion. IPAF is characterized by a lower survival rate compared to CTD-ILD, and a relatively low risk of CTD transformation.

21 September 2022 in PULMONOLOGIYA
Verified
Journal Article
Open access
PDF file
LAL. A. Akulkina
L. A. Akulkina
MBM. Yu. Brovko
M. Yu. Brovko
ASAnastasia Shchepalina
Anastasia Shchepalina
VSVictoria Sholomova
Victoria Sholomova
AKA. A. Kitbalian
A. A. Kitbalian
SMSergey V. Moiseev
Sergey V. Moiseev
Interstitial lung diseases (ILDs) is a wide group of diffuse parenchymal lung diseases that can lead to interstitial pulmonary fibrosis. Clinical course of all ILDs, in particular with chronic fibrosing phenotype, can be complicated by an acute exacerbation caused by infection. Today, data about clinical course of COVID-19 in patients with progressive interstitial lung diseases is limited. In this case we described the course of COVID-19 infection in a patient with an interstitial pneumonia with autoimmune features (IPAF) and a progressive pulmonary fibrosis (PPF). We also discussed the typical features of COVID-19 in this population and the directions for further research.

2 October 2026 in Siberian Journal of Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
AMA. S. Moiseev
A. S. Moiseev
NBNikolay Bulanov
Nikolay Bulanov
EFE. R. Fedulova
E. R. Fedulova
EMElena Mershina
Elena Mershina
SMSergey V. Moiseev
Sergey V. Moiseev
СМС. В. Моисеев
С. В. Моисеев
Introduction. Fabry disease is an X-linked lysosomal storage disorder with multisystem involvement, the clinical manifestations and severity of which differ significantly between males and females. The diversity of early symptoms and target organ damage often leads to delayed diagnosis, while timely diagnosis is essential for early initiation of specific therapy. Aim: To study the clinical features of Fabry disease in males and females in the Russian population over the period from 2015 to 2026 for early diagnosis of the disease. Material and Methods. A retrospective cohort study with a comparative analysis of clinical manifestations of Fabry disease in adult males and females was conducted. The cohort study, covering the period from 2015 to 2026, included 259 adult patients with Fabry disease confirmed by molecular genetic testing (150 males and 109 females; median age 45.5 years). To assess target organ damage, daily albuminuria, serum creatinine levels, 24-hour Holter ECG monitoring, echocardiography, cardiac and brain magnetic resonance imaging (MRI) were performed. Clinical manifestations were assessed in the overall cohort and separately in males and females. Results. The majority of patients had typical early manifestations of Fabry disease from childhood or adolescence, including neuropathic pain in the hands and feet (67.6%), angiokeratomas (33.6%), cornea verticillata (58.3%), hypohidrosis (49.4%), and/or gastrointestinal symptoms (19.3%). The target-organ involvement, that is, kidney, heart, and brain disease, was detected in 80.3%, 61.0%, and 48.3% of patients, respectively. Despite the relatively young age of the examined patients, many presented various disease outcomes, such as dailysis-dependent chronic renal failure (20.1%), stroke (18.1%), including recurrent stroke, and/or severe left ventricular hypertrophy (LVH) (21.6%) accompanied by arrhythmias and/or chronic heart failure. Mortality during follow-up was 12.7%. Male patients had a more severe clinical course of Fabry disease and developed adverse outcomes at younger age. Conclusion. Fabry disease should be suspected in adults patients with nephropathy or left ventricular hypertrophy of unknown origin and/or stroke at a young age, particularly when these findings are accompanied by typical early manifestations of the disease.

8 February 2026 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
EGE. V. Gagarina
E. V. Gagarina
EMElena Mershina
Elena Mershina
RMRoman Myasnikov
Roman Myasnikov
АMА. S. Moiseev
А. S. Moiseev
OKOlga Kulikova
Olga Kulikova
Valentin SinitsynValentin Sinitsyn
Valentin Sinitsyn
Aim. Cardiac involvement in Anderson-Fabry disease (AFD) is often characterized by left ventricular hypertrophy (LVH), which can be mistaken for hypertrophic cardiomyopathy (HCM). The aim was to analyze and compare morphological and functional cardiac changes using multiparametric magnetic resonance imaging (MRI) in patients with AFD, HCM, and healthy volunteers. Material and methods. The study included 131 patients with HCM, 42 patients with AFD, and 18 healthy volunteers. Multiparametric cardiac MRI was performed using a 3T scanner. Results. LVH was detected in 55% of patients with AFD. Signs of myocardial fibrosis were more common in HCM than in AFD+LVH (86% vs 35%, p<0,05). Native T1 and T2 mapping and extracellular volume fraction values were higher in the HCM group than in the AFD+LVH group as follows: 1269,4±52,7 vs 1144,5±30,6 ms, 41,6±3,9 vs 40,0±1,4 ms, 0,33±0,06 vs 0,27±0,02 ms, respectively (p<0,05). Native T1 mapping values in AFD patients without LVH were significantly lower than in healthy volunteers as follows: 1124,6±45,0 vs 1207,7±40,0 ms, respectively (p<0,05). Conclusion. Native T1 mapping values in AFD, regardless of LVH, are lower than those in patients with HCM and healthy volunteers and can be used in the early diagnosis of myocardial involvement in AFD.